Crossmark

FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

Published Online: 2016-01-16

Published Print: 2016-12

Authors

Yeo, Dannel

He, Hong

Patel, Oneel

Lowy, Andrew M.

Baldwin, Graham S.

Nikfarjam, Mehrdad
Funding

Funding for this research was provided by:

National Health and Medical Research Council (508908, 1020983)

National Institutes of Health (CA155620-01)

Sir Edward Dunlop Medical Research Foundation
License Information

Text and Data Mining valid from 2016-01-16

Version of Record valid from 2016-01-16
More Information

Article History

Received: 12 August 2015

Accepted: 8 January 2016

First Online: 16 January 2016

Document is current